U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06868797) titled 'Acute Reno-Cardiac Action of Dapagliflozin in Advanced Heart Failure Patients on Heart Transplant Waiting List' on Feb. 17.
Brief Summary: Heart failure affects 1 to 2% of the adult population in developed countries, representing about 55 million people worldwide.
Advanced heart failure is a condition where the heart can no longer provide sufficient cardiac output or equilibrate pressures within its chambers, leading to symptoms such as shortness of breath, fatigue, and water and salt retention.
Heart failure affects the kidneys by reducing blood flow directed to them, sometimes leading to kidney congestion. In the long term, thi...